For a more detailed analysis, you can explore the full Outlook report here: https://insights.citeline.com/in-vivo/outlook/
Scrip 100 Rankings Shake-Up: AstraZeneca, Lilly, Novo Nordisk And Amgen Climb Higher - Clone - Clone
Listen to this article
Other top 20 players also moved up in the rankings fired by double-digit growth. Lilly, Novo Nordisk and Amgen all gained on the Scrip 100, which is based on FY 2024 pharmaceutical sales.
data
Keep up with the top pharma business news of the week. On the go.
More from Scrip
in the expanding and competitive field of obesity therapy clinical trials, one trend is increasingly causing a headache: placebo-arm participants dropping out or using “off-protocol” weight-loss treatments while on trial.
Sponsored by :
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.